Evaluation of a new bead-based assay to measure levels of human tissue factor antigen in extracellular vesicles in plasma.
COVID‐19
biomarker
extracellular vesicle
thrombosis
tissue factor
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
12
01
2022
revised:
03
02
2022
accepted:
08
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Circulating tissue factor (TF)-expressing extracellular vesicles (EVs) are associated with thrombosis in several diseases, such as coronavirus disease 2019 (COVID-19). Activity assays have higher sensitivity and specificity compared to antigen assays for measuring TF+ EVs in plasma. The MACSPlex Exosome Kit is designed to detect 37 exosomal surface epitopes, including TF, on EVs in plasma using various fluorescently labeled beads. The different EV-bead complexes are detected by flow cytometry. A recent study used the MACSPlex Exosome Kit to measure levels of TF+ EVs in serum from patients with COVID-19. To evaluate the ability of the MACSPlex Exosome Kit to detect TF on EVs in plasma. We measured levels of TF+ EVs isolated from plasma with or without TF detected using our in-house EVTF activity assay and the MACSPlex Exosome Kit. The MACSPlex Exosome Kit gave a very low TF antigen signal (TF bead signal) compared to platelet-derived CD41b+ EVs, which was used as a control. Lipopolysaccharide (LPS) increased levels of EVTF activity but not TF bead signal in four donors. Inhibition of TF reduced levels of EVTF activity but did not affect the TF bead signal in EVs isolated from plasma from LPS-treated blood. Finally, we found no correlation between levels of EVTF activity and TF bead signal in EVs isolated from plasma from ovarian cancer patients ( Our data suggest that the MACSPlex Exosome Kit gives a nonspecific signal for TF and does not have the sensitivity to detect TF+ EVs in plasma.
Sections du résumé
Background
UNASSIGNED
Circulating tissue factor (TF)-expressing extracellular vesicles (EVs) are associated with thrombosis in several diseases, such as coronavirus disease 2019 (COVID-19). Activity assays have higher sensitivity and specificity compared to antigen assays for measuring TF+ EVs in plasma. The MACSPlex Exosome Kit is designed to detect 37 exosomal surface epitopes, including TF, on EVs in plasma using various fluorescently labeled beads. The different EV-bead complexes are detected by flow cytometry. A recent study used the MACSPlex Exosome Kit to measure levels of TF+ EVs in serum from patients with COVID-19.
Objectives
UNASSIGNED
To evaluate the ability of the MACSPlex Exosome Kit to detect TF on EVs in plasma.
Methods
UNASSIGNED
We measured levels of TF+ EVs isolated from plasma with or without TF detected using our in-house EVTF activity assay and the MACSPlex Exosome Kit.
Results
UNASSIGNED
The MACSPlex Exosome Kit gave a very low TF antigen signal (TF bead signal) compared to platelet-derived CD41b+ EVs, which was used as a control. Lipopolysaccharide (LPS) increased levels of EVTF activity but not TF bead signal in four donors. Inhibition of TF reduced levels of EVTF activity but did not affect the TF bead signal in EVs isolated from plasma from LPS-treated blood. Finally, we found no correlation between levels of EVTF activity and TF bead signal in EVs isolated from plasma from ovarian cancer patients (
Conclusion
UNASSIGNED
Our data suggest that the MACSPlex Exosome Kit gives a nonspecific signal for TF and does not have the sensitivity to detect TF+ EVs in plasma.
Identifiants
pubmed: 35284777
doi: 10.1002/rth2.12677
pii: S2475-0379(22)01168-2
pmc: PMC8897283
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12677Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL155657
Pays : United States
Informations de copyright
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878-882
pubmed: 33267656
Thromb Res. 2019 Oct;182:64-74
pubmed: 31450010
Blood. 2013 Sep 12;122(11):1873-80
pubmed: 23798713
EBioMedicine. 2021 May;67:103369
pubmed: 33971404
Blood Adv. 2021 Feb 9;5(3):628-634
pubmed: 33560376
Blood. 1987 Aug;70(2):490-3
pubmed: 3607285
J Thromb Haemost. 2007 Mar;5(3):520-7
pubmed: 17166244
Thromb Res. 2016 Mar;139:90-7
pubmed: 26916302
J Thromb Haemost. 2013 Jul;11(7):1353-63
pubmed: 23621622
J Extracell Vesicles. 2016 Feb 19;5:29975
pubmed: 26901056
Thromb Res. 2012 Jan;129(1):80-5
pubmed: 21737126
J Thromb Haemost. 2014 Nov;12(11):1932-4
pubmed: 25186801
Thromb Res. 2017 Feb;150:65-72
pubmed: 28043041
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725
pubmed: 29437578
Res Pract Thromb Haemost. 2021 May 18;5(4):e12525
pubmed: 34027292
J Thromb Haemost. 2021 Nov;19(11):2652-2658
pubmed: 34418279
Res Pract Thromb Haemost. 2018 Nov 20;3(1):44-48
pubmed: 30656275
Semin Thromb Hemost. 2010 Nov;36(8):865-75
pubmed: 21049387